Related Experiment Video

Updated: Nov 10, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.0K

Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease

Gregory J Botwin, Dalin Li, Jane Figueiredo

    Medrxiv : the Preprint Server for Health Sciences
    |April 6, 2021
    PubMed

    Insights

    Patients with inflammatory bowel disease (IBD) experienced similar side effects after mRNA COVID-19 vaccination compared to the general population. Biologic therapy may even reduce adverse events in these individuals.

    Area of Science:

    • Immunology
    • Vaccinology
    • Gastroenterology

    Background:

    • Patients with immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD), were underrepresented in SARS-CoV-2 mRNA vaccine clinical trials.
    • Understanding the safety profile of mRNA vaccines in this population is crucial due to their use of immunosuppressive and biologic therapies.

    Approach:

    • This study evaluated post-mRNA vaccination adverse events (AE) in 246 adults with IBD enrolled in a longitudinal vaccine registry.
    • AE data were collected and analyzed to compare frequencies with the general population and identify potential influencing factors.

    Key Points:

    • The overall frequency of adverse events following mRNA vaccination in IBD patients was comparable to that observed in the general population.
    • Adverse events were more prevalent in younger individuals and those with a history of COVID-19 infection.
    • Interestingly, patients receiving biologic therapy reported fewer adverse events.

    Conclusions:

    • Individuals with IBD and other IMID undergoing treatment with commonly prescribed therapies can be reassured regarding mRNA vaccine safety.
    • The risk of adverse events following vaccination is not elevated in patients on biologic therapy and may potentially be reduced.

    More Related Videos

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    3.1K
    Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice07:34

    Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

    Published on: December 16, 2021

    2.9K

    Related Concept Videos

    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    274
    Inflammatory Bowel Disease II: Crohn's Disease01:30

    Inflammatory Bowel Disease II: Crohn's Disease

    Introduction
    Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
    Crohn's disease
    Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
    553
    Inflammatory Bowel Disease I: Ulcerative Colitis01:27

    Inflammatory Bowel Disease I: Ulcerative Colitis

    Introduction
    Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
    Risk Factors
    The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
    523
    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

    Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
    Diagnostic studies
    A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
    482
    Inflammatory Bowel Disease V: Surgical Management01:21

    Inflammatory Bowel Disease V: Surgical Management

    Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
    Here are some common surgical interventions for IBD:
    285
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    304